Clinical trial
A Phase 2, Double-masked, Randomized, Vehicle-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of VVN539 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
NCT05451329 is registered in ClinicalTrials.gov with VivaVision Biotech, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Double-masked, Randomized, Vehicle-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of VVN539 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
- Lead sponsor
- VivaVision Biotech, Inc
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 12, 2022
- Completion date
- December 22, 2022
- Enrollment
- 68 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.